New drug combo aims to improve stomach cancer surgery outcomes
NCT ID NCT07522151
First seen Apr 14, 2026 · Last updated May 09, 2026 · Updated 2 times
Summary
This study tests whether adding the drug adebrelimab to standard chemotherapy (S-1 and oxaliplatin) before and after surgery helps people with stomach or gastroesophageal junction cancer live longer without the cancer returning. About 874 adults aged 18-74 with locally advanced, resectable cancer will participate. The study is double-blind, meaning neither patients nor doctors know who gets the new drug versus a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 10000, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.